TOP TEN perturbations for 1552852_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552852_a_at
Selected probe(set): 1552852_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552852_a_at (1552852_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

aflatoxin B1 study 2 (1.6 uM; Hep-G2) / vehicle (DMSO) treated Hep-G2 cell sample

Relative Expression (log2-ratio):3.0935125
Number of Samples:3 / 9
Experimental aflatoxin B1 study 2 (1.6 uM; Hep-G2)
Hep-G2 cells exposed to 1.6 uM aflatoxin B1 (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

cisplatin study 7 (48h) / vehicle (PBS) treated HepG2 cell sample

Relative Expression (log2-ratio):2.5416522
Number of Samples:3 / 9
Experimental cisplatin study 7 (48h)
HepG2 cells exposed to 20μM cisplatin in PBS solvent for 48 hours. ATC code:
Control vehicle (PBS) treated HepG2 cell sample
HepG2 cells exposed to 0.5% PBS solvent for 48 hours.

adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):2.1571217
Number of Samples:3 / 21
Experimental adefovir study 1 (50uM)
HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

TNF-ɑ study 19 / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.7879896
Number of Samples:3 / 17
Experimental TNF-ɑ study 19
Bronchial epithelial cells (NHBE) treated with 100 ng/ml recombinant human tumor necrosis factor alpha (TNF-ɑ; vendor: PeproTech / catalog number: 300-01A / catalog name: TGF-ɑ) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

chlorambucil study 3 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):1.660871
Number of Samples:3 / 19
Experimental chlorambucil study 3 (48h)
HepG2 cells exposed to 20μM chlorambucil in DMSO solvent for 48 hours. ATC code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

cisplatin study 4 (20uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):1.5280523
Number of Samples:3 / 12
Experimental cisplatin study 4 (20uM)
HepG2 cells treated with compound: cisplatin (20uM; CAS no.:15663-27-1) for 24 hours. Cisplatin is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.

atopic dermatitis study 20 (lesional; placebo; baseline) / normal skin tissue

Relative Expression (log2-ratio):-1.4464412
Number of Samples:6 / 2
Experimental atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.
Control normal skin tissue
Skin tissue biopsies obtained from control subjects.

quercetin study 4 (12h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):1.3934512
Number of Samples:3 / 12
Experimental quercetin study 4 (12h)
HepG2 cells exposed to 50μM quercetin in DMSO solvent for 12 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 12 hours.

resorcinol study 1 (48h) / vehicle (EtOH) treated HepG2 cell sample

Relative Expression (log2-ratio):1.3841605
Number of Samples:3 / 6
Experimental resorcinol study 1 (48h)
HepG2 cells exposed to 2mM resorcinol in EtOH solvent for 48 hours. ATC code:,
Control vehicle (EtOH) treated HepG2 cell sample
HepG2 cells exposed to EtOH solvent for 48 hours.

quercetin study 4 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):1.3719625
Number of Samples:3 / 7
Experimental quercetin study 4 (24h)
HepG2 cells exposed to 50μM quercetin in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.